Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced Progressive Adrenocortical Carcinoma
2024-517205-82-00Phase 2Authorised
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in adrenal cancer (ACC), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Primary endpoints: Objective Response Rate, Progression-Free Survival and 2 more. Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on 2024-517205-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517205-82-00.